title: Dose modification of anti-TNF in rheumatoid arthritis and estimated economical impact: a review of observational studies.
abstract: Anti-TNF drugs indicated for the treatment of moderate-to-severe active rheumatoid arthritis (RA) presents similar efficacy, safety and potential toxicity profiles, with more than 10 years' treatment experience. Several pharmacoeconomic evaluations had demonstrated their favorable cost-effectiveness profile in RA patients, based on pivotal clinical studies data from different countries and perspectives. However, in clinical practice, individual profiles of patients and drugs leads to dose modifications that may be associated with substantial cost deviations. Here, we further discuss the effect of dose titration of these biological drugs in clinical practice over their RA cost-effectiveness profiles.
authors.affiliation: Specialist in Hospital Pharmacy, Pharmacy Service, Pharmacy Department, Hospital de Sagunto, Avda Ramon y Cajal s/n Sagunto E-46520 Valencia, Spain.
authors.forename: Joaquín
authors.initials: J
authors.lastname: Borrás-Blasco
authors.forename: Andres
authors.initials: A
authors.lastname: Navarro Ruiz
mesh_terms: D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000191:economics / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000191:economics; D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D004305:Dose-Response Relationship, Drug; D017850:Economics, Pharmaceutical; D006801:Humans; D012720:Severity of Illness Index; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D018501:Antirheumatic Agents; D014409:Tumor Necrosis Factor-alpha
keywords: adalimumab; anti-TNF; cost–effectiveness; dose modification; etanercept; infliximab; real-world data; rheumatoid arthritis